Controlling Shareholder Randal J. Kirk Sells $15.75 Million in Precigen Stock
PGEN has more than doubled off its 52-week low of $1.11 on elevated volume (2.7× avg).
Summary
Randal J. Kirk, a Director and controlling shareholder of Precigen, Inc., sold 4.77 million shares of common stock for $15.75 million, following a concurrent Schedule 13D/A filing reporting the same disposition.
Key Events · Ownership and Investor Activity · PGEN
-
Significant Insider Sale
Randal J. Kirk, a Director and controlling shareholder, sold 4,772,781 shares of Precigen common stock.
-
Substantial Value
The total value of the shares sold amounted to $15,750,177.
-
Timing with Prior Disclosure
This Form 4 provides the detailed transaction data for the sale previously reported in a Schedule 13D/A filed on the same day.
-
Context of Financial Performance
The sale follows the company's recent report of a significant net loss for 2025 and the securing of $100 million in debt.
Analysis · PGEN · Life Sciences
This Form 4 details the significant sale of Precigen shares by Randal J. Kirk, a Director and controlling shareholder, which was also reported in a concurrent Schedule 13D/A. The disposition of over $15.75 million worth of stock, representing 1.15% of the company's market capitalization, by a key insider and controlling figure, sends a strong negative signal to the market. This transaction occurs shortly after the company reported a substantial net loss for 2025 and secured additional debt, raising concerns about insider confidence amidst financial challenges. Investors should note the scale of this sale by a major stakeholder.
At the time of this filing, PGEN was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.11 to $5.47. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.